Hui-Teng Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hui-Teng Cheng has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Kuan-Yu Hung
Division of Nephrology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
13 shared publications - Chih-Kang Chiang
Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei 100233, Taiwan
10 shared publications - Jenq-Wen Huang
Nephrology division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
10 shared publications - Raphael Kopan
Division of Developmental Biology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
9 shared publications - Chung-Jen Yen
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
7 shared publications Chen-Pin Hsu
National Tsing Hua University
4 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Wiley in Advanced Science
LepR‐Lineage Cells Represent the Main Target of the Nociceptive CGRP Pathway in White Adipose Tissue Browning
Sympathetic innervation regulates white adipose tissue (WAT) browning; however, the roles of nociceptive neurons and their associated target cells remain unknown. Here, we used single‐nucleus RNA sequencing to profile adipose populations and genetic lineage tracing to identify LepR‐lineage stromal/progenitor cells contributing to cold‐induced WAT browning. Ablation of these cells using LepR‐Cre‐inducible DTR transgenic mice resulted in a decrease in the percentage of UCP1+ cells under cold conditions. The WAT browning process is controlled by peripheral nociceptive nerve‐derived calcitonin gene‐related peptide (CGRP), which was associated with reduced WAT browning and loss of LepR‐lineage cells during intermittent fasting (IF), but not during cold exposure. Local antagonist experiments targeting the transient receptor potential cation channels TRPV1 and TRPM8 were associated with opposing changes in CGRP immunoreactivity and WAT browning. These findings support a condition‐dependent role for nociceptive CGRP signaling in WAT remodeling.
- 9 November 2026
- Published by Wiley in Advanced Science
Open AccessLepR‐Lineage Cells Represent the Main Target of the Nociceptive CGRP Pathway in White Adipose Tissue Browning
Sympathetic innervation regulates white adipose tissue (WAT) browning; however, the roles of nociceptive neurons and their associated target cells remain unknown. Here, we used single‐nucleus RNA sequencing to profile adipose populations and genetic lineage tracing to identify LepR‐lineage stromal/progenitor cells contributing to cold‐induced WAT browning. Ablation of these cells using LepR‐Cre‐inducible DTR transgenic mice resulted in a decrease in the percentage of UCP1+ cells under cold conditions. The WAT browning process is controlled by peripheral nociceptive nerve‐derived calcitonin gene‐related peptide (CGRP), which was associated with reduced WAT browning and loss of LepR‐lineage cells during intermittent fasting (IF), but not during cold exposure. Local antagonist experiments targeting the transient receptor potential cation channels TRPV1 and TRPM8 were associated with opposing changes in CGRP immunoreactivity and WAT browning. These findings support a condition‐dependent role for nociceptive CGRP signaling in WAT remodeling.
- 18 March 2024
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (2) , e1953
A quantitative review of nanotechnology‐based therapeutics for kidney diseases
Kidney‐specific nanocarriers offer a targeted approach to enhance therapeutic efficacy and reduce off‐target effects in renal treatments. The nanocarriers can achieve organ or cell specificity via passive targeting and active targeting mechanisms. Passive targeting capitalizes on the unique physiological traits of the kidney, with factors like particle size, charge, shape, and material properties enhancing organ specificity. Active targeting, on the other hand, achieves renal specificity through ligand‐receptor interactions, modifying nanocarriers with molecules, peptides, or antibodies for receptor‐mediated delivery. Nanotechnology‐enabled therapy targets diseased kidney tissue by modulating podocytes and immune cells to reduce inflammation and enhance tissue repair, or by inhibiting myofibroblast differentiation to mitigate renal fibrosis. This review summarizes the current reports of the drug delivery systems that have been tested in vivo, identifies the nanocarriers that may preferentially accumulate in the kidney, and quantitatively compares the efficacy of various cargo‐carrier combinations to outline optimal strategies and future research directions.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies
- 18 March 2024
- Published by Wiley in WIREs Nanomedicine and Nanobiotechnology
- Vol. 16 (2) , e1953
A quantitative review of nanotechnology‐based therapeutics for kidney diseases
Kidney‐specific nanocarriers offer a targeted approach to enhance therapeutic efficacy and reduce off‐target effects in renal treatments. The nanocarriers can achieve organ or cell specificity via passive targeting and active targeting mechanisms. Passive targeting capitalizes on the unique physiological traits of the kidney, with factors like particle size, charge, shape, and material properties enhancing organ specificity. Active targeting, on the other hand, achieves renal specificity through ligand‐receptor interactions, modifying nanocarriers with molecules, peptides, or antibodies for receptor‐mediated delivery. Nanotechnology‐enabled therapy targets diseased kidney tissue by modulating podocytes and immune cells to reduce inflammation and enhance tissue repair, or by inhibiting myofibroblast differentiation to mitigate renal fibrosis. This review summarizes the current reports of the drug delivery systems that have been tested in vivo, identifies the nanocarriers that may preferentially accumulate in the kidney, and quantitatively compares the efficacy of various cargo‐carrier combinations to outline optimal strategies and future research directions.This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies
- Top Cited Papers
- 17 November 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (1) , 89-97
Worldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015
OBJECTIVE: The annual risk among patients with diabetes of reaching end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000–2015. RESEARCH DESIGN AND METHODS: The annual incidence of ESRD among patients with diabetes was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtraction of the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated with use of the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively. RESULTS: Data were obtained from 142 countries, covering 97.3% of the world population. The global percentage of the prevalent ESRD patients with diabetes increased from 19.0% in 2000 to 29.7% in 2015 worldwide, while the percentage of incident ESRD patients due to diabetes increased from 22.1% to 31.3%. The global annual incidence of ESRD among patients with diabetes increased from 375.8 to 1,016.0/million with diabetes during 2000–2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European patients with diabetes ranged from one-half (309.2 vs. 544.6) to one-third (419.4 vs. 1,245.2) of the rates of the Western Pacific population during 2000–2015. CONCLUSIONS: Great and nonrandom geographic variation in the annual rates among patients with diabetes of reaching ESRD suggests that distinct health care, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat diabetes-related ESRD require better patient susceptibility stratification.
- 17 November 2020
- Published by American Diabetes Association in Diabetes Care
- Vol. 44 (1) , 89-97
Top Cited PapersWorldwide Epidemiology of Diabetes-Related End-Stage Renal Disease, 2000–2015
OBJECTIVE: The annual risk among patients with diabetes of reaching end-stage renal disease (ESRD) is largely unknown worldwide. This study aimed to compare the incidence of diabetes-related ESRD by creating a global atlas during 2000–2015. RESEARCH DESIGN AND METHODS: The annual incidence of ESRD among patients with diabetes was calculated as the quotient of the number of incident ESRD patients with diabetes divided by the total number of patients with diabetes after subtraction of the number with existing ESRD. The estimated ESRD prevalence and annual incidence were validated with use of the data provided by Fresenius Medical Care, Germany, and previously reported data, respectively. RESULTS: Data were obtained from 142 countries, covering 97.3% of the world population. The global percentage of the prevalent ESRD patients with diabetes increased from 19.0% in 2000 to 29.7% in 2015 worldwide, while the percentage of incident ESRD patients due to diabetes increased from 22.1% to 31.3%. The global annual incidence of ESRD among patients with diabetes increased from 375.8 to 1,016.0/million with diabetes during 2000–2015. The highest average rates were observed in the Western Pacific Region. Comparatively, the rates of incident ESRD among European patients with diabetes ranged from one-half (309.2 vs. 544.6) to one-third (419.4 vs. 1,245.2) of the rates of the Western Pacific population during 2000–2015. CONCLUSIONS: Great and nonrandom geographic variation in the annual rates among patients with diabetes of reaching ESRD suggests that distinct health care, environmental, and/or genetic factors contribute to the progression of diabetic kidney disease. Measures to prevent and treat diabetes-related ESRD require better patient susceptibility stratification.
- 3 October 2019
- Published by Wiley in The Journal of Pathology
- Vol. 250 (1) , 55-66
Inflammatory macrophages switch to CCL17‐expressing phenotype and promote peritoneal fibrosis
Peritoneal fibrosis remains a problem in kidney failure patients treated with peritoneal dialysis. Severe peritoneal fibrosis with encapsulation or encapsulating peritoneal sclerosis is devastating and life‐threatening. Although submesothelial fibroblasts as the major precursor of scar‐producing myofibroblasts in animal models and M2 macrophage (Mϕ)‐derived chemokines in peritoneal effluents of patients before diagnosis of encapsulating peritoneal sclerosis have been identified, attenuation of peritoneal fibrosis is an unmet medical need partly because the mechanism for cross talk between Mϕs and fibroblasts remains unclear. We use a sodium hypochlorite‐induced mouse model akin to clinical encapsulated peritoneal sclerosis to study how the peritoneal Mϕs activate fibroblasts and fibrosis. Sodium hypochlorite induces the disappearance of CD11bhighF4/80high resident Mϕs but accumulation of CD11bintF4/80int inflammatory Mϕs (InfMϕs) through recruiting blood monocytes and activating local cell proliferation. InfMϕs switch to express chemokine (C‐C motif) ligand 17 (CCL17), CCL22, and arginase‐1 from day 2 after hypochlorite injury. More than 75% of InfMϕs undergo genetic recombination by Csf1r‐driven Cre recombinase, providing the possibility to reduce myofibroblasts and fibrosis by diphtheria toxin‐induced Mϕ ablation from day 2 after injury. Furthermore, administration of antibody against CCL17 can reduce Mϕs, myofibroblasts, fibrosis, and improve peritoneal function after injury. Mechanistically, CCL17 stimulates migration and collagen production of submesothelial fibroblasts in culture. By breeding mice that are induced to express red fluorescent protein in Mϕs and green fluorescence protein (GFP) in Col1a1‐expressing cells, we confirmed that Mϕs do not produce collagen in peritoneum before and after injury. However, small numbers of fibrocytes are found in fibrotic peritoneum of chimeric mice with bone marrow from Col1a1‐GFP reporter mice, but they do not contribute to myofibroblasts. These data demonstrate that InfMϕs switch to pro‐fibrotic phenotype and activate peritoneal fibroblasts through CCL17 after injury. CCL17 blockade in patients with peritoneal fibrosis may provide a novel therapy. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 3 October 2019
- Published by Wiley in The Journal of Pathology
- Vol. 250 (1) , 55-66
Inflammatory macrophages switch to CCL17‐expressing phenotype and promote peritoneal fibrosis
Peritoneal fibrosis remains a problem in kidney failure patients treated with peritoneal dialysis. Severe peritoneal fibrosis with encapsulation or encapsulating peritoneal sclerosis is devastating and life‐threatening. Although submesothelial fibroblasts as the major precursor of scar‐producing myofibroblasts in animal models and M2 macrophage (Mϕ)‐derived chemokines in peritoneal effluents of patients before diagnosis of encapsulating peritoneal sclerosis have been identified, attenuation of peritoneal fibrosis is an unmet medical need partly because the mechanism for cross talk between Mϕs and fibroblasts remains unclear. We use a sodium hypochlorite‐induced mouse model akin to clinical encapsulated peritoneal sclerosis to study how the peritoneal Mϕs activate fibroblasts and fibrosis. Sodium hypochlorite induces the disappearance of CD11bhighF4/80high resident Mϕs but accumulation of CD11bintF4/80int inflammatory Mϕs (InfMϕs) through recruiting blood monocytes and activating local cell proliferation. InfMϕs switch to express chemokine (C‐C motif) ligand 17 (CCL17), CCL22, and arginase‐1 from day 2 after hypochlorite injury. More than 75% of InfMϕs undergo genetic recombination by Csf1r‐driven Cre recombinase, providing the possibility to reduce myofibroblasts and fibrosis by diphtheria toxin‐induced Mϕ ablation from day 2 after injury. Furthermore, administration of antibody against CCL17 can reduce Mϕs, myofibroblasts, fibrosis, and improve peritoneal function after injury. Mechanistically, CCL17 stimulates migration and collagen production of submesothelial fibroblasts in culture. By breeding mice that are induced to express red fluorescent protein in Mϕs and green fluorescence protein (GFP) in Col1a1‐expressing cells, we confirmed that Mϕs do not produce collagen in peritoneum before and after injury. However, small numbers of fibrocytes are found in fibrotic peritoneum of chimeric mice with bone marrow from Col1a1‐GFP reporter mice, but they do not contribute to myofibroblasts. These data demonstrate that InfMϕs switch to pro‐fibrotic phenotype and activate peritoneal fibroblasts through CCL17 after injury. CCL17 blockade in patients with peritoneal fibrosis may provide a novel therapy. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- Open Access
- 12 April 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 5868
Affective and cognitive rather than somatic symptoms of depression predict 3-year mortality in patients on chronic hemodialysis
Depression is more common in many medical conditions than among the general population and is associated with an increased risk of mortality. We aimed to determine whether somatic symptoms of depression were more predictive of mortality than affective and cognitive symptoms in hemodialysis patients. We conducted a prospective cohort study in which the survival outcomes of 151 subjects were followed for more than 3 years. Depression was assessed with the Taiwanese Depression Questionnaire (TDQ). Subjects with TDQ scores 19–54 (correlated with clinically significant depressive symptoms) and those with scores 15–18 had higher 3-year mortality rates than the two groups with lower scores (40.0%, 46.7%, 16.0% and 19.6%, p = 0.021, ANOVA). Affective and cognitive symptoms, including sadness, tenseness, indecisiveness and low self-confidence, and one somatic item (bodily discomfort) were associated with mortality. Affective and cognitive symptoms affected quality of life more than somatic symptoms. The somatic subscale was associated with female gender, low income and education, dialysis vintage, and low serum creatinine and albumin levels, whereas the affective and cognitive subscale was associated with less education and a low serum albumin level. In conclusion, affective and cognitive symptoms of depression may better predict long-term mortality in patients undergoing chronic hemodialysis than somatic symptoms.
- 12 April 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 5868
Open AccessAffective and cognitive rather than somatic symptoms of depression predict 3-year mortality in patients on chronic hemodialysis
Depression is more common in many medical conditions than among the general population and is associated with an increased risk of mortality. We aimed to determine whether somatic symptoms of depression were more predictive of mortality than affective and cognitive symptoms in hemodialysis patients. We conducted a prospective cohort study in which the survival outcomes of 151 subjects were followed for more than 3 years. Depression was assessed with the Taiwanese Depression Questionnaire (TDQ). Subjects with TDQ scores 19–54 (correlated with clinically significant depressive symptoms) and those with scores 15–18 had higher 3-year mortality rates than the two groups with lower scores (40.0%, 46.7%, 16.0% and 19.6%, p = 0.021, ANOVA). Affective and cognitive symptoms, including sadness, tenseness, indecisiveness and low self-confidence, and one somatic item (bodily discomfort) were associated with mortality. Affective and cognitive symptoms affected quality of life more than somatic symptoms. The somatic subscale was associated with female gender, low income and education, dialysis vintage, and low serum creatinine and albumin levels, whereas the affective and cognitive subscale was associated with less education and a low serum albumin level. In conclusion, affective and cognitive symptoms of depression may better predict long-term mortality in patients undergoing chronic hemodialysis than somatic symptoms.
- Open Access
- 1 January 2018
- Published by Ivyspring International Publisher in Theranostics
- Vol. 8 (4) , 894-905
Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in malignant cells. The consequence of this effect in non-malignant disease (hepatic fibrosis) remains unknown. This study aimed to examine the effects of sorafenib on activated hepatic stellate cells (HSCs), and develop effective therapeutic approaches to treat liver fibrosis and prevent cancer development.
- 1 January 2018
- Published by Ivyspring International Publisher in Theranostics
- Vol. 8 (4) , 894-905
Open AccessCombined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development
Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in malignant cells. The consequence of this effect in non-malignant disease (hepatic fibrosis) remains unknown. This study aimed to examine the effects of sorafenib on activated hepatic stellate cells (HSCs), and develop effective therapeutic approaches to treat liver fibrosis and prevent cancer development.
- 27 December 2017
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 26 (5-6) , 516-524
Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl4-induced hepatic fibrosis in mice
Chronic liver diseases have recently garnered substantial attention as a leading cause of death around the world. During the progression of liver fibrosis/cirrhosis induced by chronic liver injury, hepatic stellate cells (HSCs) play key roles in the regulation of liver fibrogenesis and can even accelerate the progression of hepatocellular carcinoma (HCC). Thus, inhibition of HSC activation or suppression of inflammatory cytokine secretion by HSCs may be an efficient therapeutic strategy to ameliorate liver fibrosis/cirrhosis. In this study, we demonstrated that Cellax NPs (Carboxymethylcellulose − docetaxel-conjugated nanoparticles), which are nanoscale Pegylated carboxymethylcellulose − DTX conjugates, selectively target activated HSCs and abrogate their fibrogenic properties in vitro. Furthermore, Cellax NPs alleviated CCl4-induced hepatic fibrosis and suppressed HCC progression in a clinically relevant HCC model associated with underlying liver fibrosis in vivo. Taken together, Cellax NPs demonstrate great therapeutic promise as a treatment for liver fibrosis and cancer.
- 27 December 2017
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 26 (5-6) , 516-524
Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl4-induced hepatic fibrosis in mice
Chronic liver diseases have recently garnered substantial attention as a leading cause of death around the world. During the progression of liver fibrosis/cirrhosis induced by chronic liver injury, hepatic stellate cells (HSCs) play key roles in the regulation of liver fibrogenesis and can even accelerate the progression of hepatocellular carcinoma (HCC). Thus, inhibition of HSC activation or suppression of inflammatory cytokine secretion by HSCs may be an efficient therapeutic strategy to ameliorate liver fibrosis/cirrhosis. In this study, we demonstrated that Cellax NPs (Carboxymethylcellulose − docetaxel-conjugated nanoparticles), which are nanoscale Pegylated carboxymethylcellulose − DTX conjugates, selectively target activated HSCs and abrogate their fibrogenic properties in vitro. Furthermore, Cellax NPs alleviated CCl4-induced hepatic fibrosis and suppressed HCC progression in a clinically relevant HCC model associated with underlying liver fibrosis in vivo. Taken together, Cellax NPs demonstrate great therapeutic promise as a treatment for liver fibrosis and cancer.
- Open Access
- 20 September 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 11981
A single question regarding mobility in the World Health Organization quality of life questionnaire predicts 3-year mortality in patients receiving chronic hemodialysis
Low quality of life, depression and poor quality of sleep are associated with increased mortality in hemodialysis patients. It is not clear which factor has the highest predictive power and what the core element is to explain the predictability. We thus conducted a prospective cohort study that included 151 hemodialysis adults. Three traits of interest were assessed by World Health Organization Quality of Life questionnaire, an abbreviated version (WHOQOL-BREF), Taiwanese Depression Questionnaire, and Athens Insomnia Scale, respectively. They were followed for more than 3 years and the all-cause mortality was 30.5%. The prevalence of quality of life at the lowest tertile, depression and poor quality of sleep was 19.9%, 43.0% and 74.2%, respectively. Discriminant analysis showed the standardized coefficient of each factor as 0.813, −0.289 and 0.066, indicating the highest discriminating power by quality of life to predict mortality. Question 15 “how well are you able to get around?” in the physical health domain of WHOQOL-BREF independently associated a hazard ratio of mortality 0.623 (95% confidence interval 0.423-0.918). Subjective perception of overall quality of life was more related to psycho-social-environmental factors. In conclusion, mobility is an independent and powerful predictor to long term mortality in patients on chronic hemodialysis.
- 20 September 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 11981
Open AccessA single question regarding mobility in the World Health Organization quality of life questionnaire predicts 3-year mortality in patients receiving chronic hemodialysis
Low quality of life, depression and poor quality of sleep are associated with increased mortality in hemodialysis patients. It is not clear which factor has the highest predictive power and what the core element is to explain the predictability. We thus conducted a prospective cohort study that included 151 hemodialysis adults. Three traits of interest were assessed by World Health Organization Quality of Life questionnaire, an abbreviated version (WHOQOL-BREF), Taiwanese Depression Questionnaire, and Athens Insomnia Scale, respectively. They were followed for more than 3 years and the all-cause mortality was 30.5%. The prevalence of quality of life at the lowest tertile, depression and poor quality of sleep was 19.9%, 43.0% and 74.2%, respectively. Discriminant analysis showed the standardized coefficient of each factor as 0.813, −0.289 and 0.066, indicating the highest discriminating power by quality of life to predict mortality. Question 15 “how well are you able to get around?” in the physical health domain of WHOQOL-BREF independently associated a hazard ratio of mortality 0.623 (95% confidence interval 0.423-0.918). Subjective perception of overall quality of life was more related to psycho-social-environmental factors. In conclusion, mobility is an independent and powerful predictor to long term mortality in patients on chronic hemodialysis.
- Open Access
- 1 March 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (13) , e6525
The effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis
Patients with end-stage renal disease (ESRD) who are on hemodialysis have high risk of vascular diseases. Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis. This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outcomes. Primary outcomes, including death from any cause, and secondary outcomes, including admission for stroke, myocardial infarction, and heart failure, were examined. Compared to the nonuser group, the adjusted HRs for mortality of the nonadherence group and the adherence group were 0.81 (95% CI: 0.76–0.86) and 0.98 (95% CI: 0.86–1.13), respectively. Cardiovascular events were more frequent in patients with ESRD receiving ACEIs /ARBs than in nonusers. Compared with nonusers, the hazard of secondary outcome significantly increased in the nonadherence group or adherence group in 10 years follow-up. Compared with patients with diabetes or chronic kidney disease, patients on hemodialysis may not experience the same cardiovascular and cerebrovascular benefits from ACEIs/ARBs use.
- 1 March 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (13) , e6525
Open AccessThe effectiveness and safety of angiotensin-converting enzyme inhibition or receptor blockade in vascular diseases in patients with hemodialysis
Patients with end-stage renal disease (ESRD) who are on hemodialysis have high risk of vascular diseases. Our study sought to examine whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin type 1 receptor blockers (ARBs) could reduce the frequencies of cardiovascular and cerebrovascular events in patients receiving hemodialysis using the medication possession ratio (MPR) method of analysis. This retrospective cohort study identified cases of ESRD with dialysis from the National Health Insurance Research Database between 1999 and 2006, and used Cox-regression methods to evaluate risk of poor outcomes. Primary outcomes, including death from any cause, and secondary outcomes, including admission for stroke, myocardial infarction, and heart failure, were examined. Compared to the nonuser group, the adjusted HRs for mortality of the nonadherence group and the adherence group were 0.81 (95% CI: 0.76–0.86) and 0.98 (95% CI: 0.86–1.13), respectively. Cardiovascular events were more frequent in patients with ESRD receiving ACEIs /ARBs than in nonusers. Compared with nonusers, the hazard of secondary outcome significantly increased in the nonadherence group or adherence group in 10 years follow-up. Compared with patients with diabetes or chronic kidney disease, patients on hemodialysis may not experience the same cardiovascular and cerebrovascular benefits from ACEIs/ARBs use.
- 1 December 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1850 (12) , 2506-2517
Ferritin heavy chain mediates the protective effect of heme oxygenase-1 against oxidative stress
- 1 December 2015
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1850 (12) , 2506-2517
Ferritin heavy chain mediates the protective effect of heme oxygenase-1 against oxidative stress